CohBar completes phase 1a and initiates phase 1b stage of clinical trial of CB4211 under development for NASH and ObesityMilestone for first mitochondrial based therapeutic in humans
Its established molecular architecture and documented metal-binding properties have made it a valuable reference compound for studies examining ligand-metal interactions, metallopeptide pharmacology, structure-function relationships, and copper-dependent regulatory mechanisms.
Usually, over 100 uremic toxins can act as markers for this condition, present in the bloodstream at differing levels
Common Research Stack Combinations
The formula is built around high-purity glutathione (made up of glutamic acid, cysteine and glycine) and uses liposomal delivery with CeLLg8 technology to support better absorption
It also plays well with other ingredients so it fits into most skincare routines